Pasithea Therapeutics' trial for PAS-004 can advance to a higher dosage, showing no dose-limiting toxicities or rash so far.
Quiver AI Summary
Pasithea Therapeutics Corp. announced that the external Safety Review Committee has recommended proceeding to the next dose level of 22mg in its Phase 1 clinical trial of PAS-004, a new macrocyclic MEK inhibitor aimed at treating neurofibromatosis type 1 and other cancers. The recommendation follows the review of safety data indicating no dose-limiting toxicities or rash among the first 14 patients treated, which differentiates PAS-004 from other MEK inhibitors that often cause rashes leading to discontinuation. CEO Dr. Tiago Reis Marques expressed optimism regarding the safety profile of PAS-004 and its potential to change treatment approaches for patients with NF1. The trial is ongoing and aims to assess the drug's safety, tolerability, and efficacy in patients with specific genetic mutations related to advanced solid tumors.
Potential Positives
- The external Safety Review Committee recommended proceeding to the next dose level of PAS-004, indicating confidence in its safety.
- No dose-limiting toxicities or rash have been observed in the initial patient cohorts, suggesting a favorable safety profile compared to competitor treatments.
- The company remains optimistic about the potential to change the treatment paradigm for neurofibromatosis type 1 and inoperable plexiform neurofibromas.
- Upcoming presentations of updated pharmacokinetic and pharmacodynamic data may provide additional insights and bolster investor confidence.
Potential Negatives
- While the external Safety Review Committee recommended proceeding to the next dose level, the clinical trial's future results remain uncertain and subject to significant risks and uncertainties.
- The press release contains extensive forward-looking statements, which may mislead investors regarding the actual performance and potential of PAS-004.
- The company has yet to demonstrate significant preliminary efficacy in their ongoing Phase 1 clinical trial, which may impact investor confidence.
FAQ
What is PAS-004 developed for?
PAS-004 is a next-generation macrocyclic MEK inhibitor aimed at treating neurofibromatosis type 1 (NF1) and other cancer indications.
What did the Safety Review Committee recommend?
The Safety Review Committee recommended advancing the Phase 1 clinical trial of PAS-004 to cohort 5 with a 22mg capsule dose.
Have any dose-limiting toxicities been observed with PAS-004?
No dose-limiting toxicities (DLT's) or rash have been observed to date in the trial for PAS-004.
What is the design of the clinical trial for PAS-004?
The clinical trial is a multi-center, open-label, dose escalation 3+3 study evaluating the safety and efficacy of PAS-004.
When will updated data on PAS-004 be presented?
Updated pharmacokinetic (PK) and pharmacodynamic (PD) data for PAS-004 are expected to be presented in Q1 2025.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$KTTA Hedge Fund Activity
We have seen 3 institutional investors add shares of $KTTA stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAR1 CAPITAL MANAGEMENT, LLC removed 27,696 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $150,112
- UBS GROUP AG added 6,529 shares (+17181.6%) to their portfolio in Q3 2024, for an estimated $35,387
- MORGAN STANLEY added 1,500 shares (+inf%) to their portfolio in Q3 2024, for an estimated $8,130
- TOWER RESEARCH CAPITAL LLC (TRC) removed 1,206 shares (-66.7%) from their portfolio in Q3 2024, for an estimated $6,536
- FMR LLC removed 49 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $265
- BANK OF AMERICA CORP /DE/ added 12 shares (+200.0%) to their portfolio in Q3 2024, for an estimated $65
- JPMORGAN CHASE & CO added 0 shares (+0.0%) to their portfolio in Q3 2024, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
- SRC recommended that the trial escalate to the next dose level of 22mg capsule
- No dose-limiting toxicities (DLT’s) or rash observed to date in either capsule or tablet formulations
MIAMI, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced that the external Safety Review Committee recommended that the Company’s Phase 1 clinical trial of PAS-004 in advanced cancer should proceed to cohort 5, 22mg capsule, without modification. This recommendation was based on the review of the safety data from three patients in cohort 4A (15mg capsule) and the absence of any dose limiting toxicities (DLT’s). In addition, no rash has been observed to date in any of the first 14 patients who have been dosed with PAS-004 in either capsule (12 patients) or tablet (2 patients) formulation. Rash is a common adverse event (AE) that is observed at low doses with competitor MEK inhibitors and may lead to the high discontinuation rate in real world practice.
“As we are observing substantial exposure levels of PAS-004, we remain encouraged by the safety profile PAS-004 continues to exhibit,” stated Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. “With the differentiated profile of PAS-004, we believe it is possible that this highly specific macrocyclic MEK inhibitor with a half life of greater than 60 hours may change the treatment paradigm for patients with NF1 and inoperable plexiform neurofibromas. We are looking forward to presenting updated pharmakokinetic (PK) and pharmacodynamic (PD) data during Q1 2025.”
The ongoing Phase 1 clinical trial is a multi-center, open-label, dose escalation 3+3 study design to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of PAS-004 in patients with MAPK pathway driven advanced solid tumors with a documented RAS, NF1 or RAF mutation or patients who have failed BRAF/MEK inhibition ( NCT06299839 ).
About Pasithea Therapeutics Corp.
Pasithea is a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders and RASopathies. With an experienced team of experts in the fields of neuroscience, translational medicine, and drug development, Pasithea is developing new molecular entities for the treatment of neurological disorders, including Neurofibromatosis type 1 (NF1), Solid Tumors, and Amyotrophic Lateral Sclerosis (ALS).
Forward Looking Statements
This press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company’s ongoing Phase 1 clinical trial and the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD) and preliminary efficacy of PAS-004, as well as all other statements, other than statements of historical fact, regarding the Company’s current views and assumptions with respect to future events regarding its business, as well as other statements with respect to the Company’s plans, assumptions, expectations, beliefs and objectives, the success of the Company’s current and future business strategies, product development, preclinical studies, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including risks that future clinical trial results may not match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval, as well as other factors set forth in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other filings made with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.
Pasithea Therapeutics Contact
Patrick Gaynes
Corporate Communications
[email protected]